Advertisement
Screener

RALLYBIO CORPORATION (RLYB) Payments to Acquire Equity Method Investments

2.8 / 5 stars · 68/120 Roast Me

RALLYBIO CORPORATION Payments to Acquire Equity Method Investments

RALLYBIO CORPORATION (RLYB) reported Payments to Acquire Equity Method Investments of $300.00 thousand for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-07.

Discontinued › Cash Flow › Investing Activities

us-gaap:PaymentsToAcquireEquityMethodInvestments · last filed 2022-11-07

  • RALLYBIO CORPORATION payments to acquire equity method investments for the quarter ending 2022-09-30 was $100.00K.
  • RALLYBIO CORPORATION payments to acquire equity method investments for the quarter ending 2022-06-30 was $200.00K, a 86.67% decline year-over-year.
  • RALLYBIO CORPORATION payments to acquire equity method investments for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
  • RALLYBIO CORPORATION payments to acquire equity method investments for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
  • RALLYBIO CORPORATION payments to acquire equity method investments for fiscal 2021 was $2.00M, a 5.26% increase from fiscal 2020.
  • RALLYBIO CORPORATION payments to acquire equity method investments for fiscal 2020 was $1.90M.
Period endPayments to Acquire Equity Method Investments 3 monthPayments to Acquire Equity Method Investments 6 monthPayments to Acquire Equity Method Investments 9 monthPayments to Acquire Equity Method Investments 12 month
2022-09-30$100.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07
$300.00K
derived: sum of 2 quarters · filed 2022-11-07
$300.00K
10-Q · filed 2022-11-07
$300.00K
derived: sum of 4 quarters · filed 2022-11-07
2022-06-30$200.00K
10-Q · filed 2022-08-08
$200.00K
10-Q · filed 2022-08-08
$200.00K
derived: sum of 3 quarters · filed 2022-08-08
$200.00K
derived: sum of 4 quarters · filed 2022-11-07
2022-03-31$0.00
10-Q · filed 2022-05-10
$0.00
derived: sum of 2 quarters · filed 2022-05-10
$0.00
derived: sum of 3 quarters · filed 2022-11-07
$1.50M
derived: sum of 4 quarters · filed 2022-11-07
2021-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15
$0.00
derived: sum of 2 quarters · filed 2022-11-07
$1.50M
derived: sum of 3 quarters · filed 2022-11-07
$2.00M
10-K · filed 2022-03-15
2021-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07
$1.50M
derived: sum of 2 quarters · filed 2022-11-07
$2.00M
10-Q · filed 2022-11-07
$2.30M
derived: sum of 4 quarters · filed 2022-11-07
2021-06-30$1.50M
10-Q · filed 2022-08-08
$2.00M
10-Q · filed 2022-08-08
$2.30M
derived: sum of 3 quarters · filed 2022-08-08
$2.30M
derived: sum of 4 quarters · filed 2022-08-08
2021-03-31$500.00K
10-Q · filed 2022-05-10
$800.00K
derived: sum of 2 quarters · filed 2022-05-10
$800.00K
derived: sum of 3 quarters · filed 2022-05-10
$1.80M
derived: sum of 4 quarters · filed 2022-05-10
2020-12-31$300.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15
$300.00K
derived: sum of 2 quarters · filed 2022-03-15
$1.30M
derived: sum of 3 quarters · filed 2022-03-15
$1.90M
10-K · filed 2022-03-15
2020-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10
$1.00M
derived: sum of 2 quarters · filed 2021-11-10
$1.60M
10-Q · filed 2021-11-10
2020-06-30$1.00M
10-Q · filed 2021-09-09
$1.60M
10-Q · filed 2021-09-09

Similar stocks

Stock NameCountryMarket CapPE Ratio
Acrivon Therapeutics, Inc. (ACRV)United States$0.091B-1.03
ONCOLYTICS BIOTECH INC (ONCY)$0.086B
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)United States$0.086B
Lexaria Bioscience Corp. (LEXX)$0.084B-1.92
Telomir Pharmaceuticals, Inc. (TELO)United States$0.084B
Anixa Biosciences Inc (ANIX)United States$0.096B
CITIUS ONCOLOGY, INC. (CTOR)United States$0.097B-1.49
Gain Therapeutics, Inc. (GANX)United States$0.080B-4.40
Milestone Pharmaceuticals Inc. (MIST)$0.098B-2.00
Lifevantage Corp (LFVN)United States$0.078B15.40